Allogene Therapeutics Inc (NASDAQ:ALLO) announced the publication of preclinical study results demonstrating the superior long-term in vitro myeloma-killing activity of allogeneic anti-BCMA CAR T cells from healthy donors compared with cells from multiple myeloma patients.
- The findings were published in Cancer Research Communications, the American Association for Cancer Research journal.
- Healthy donors had higher T cell counts, a higher CD4/CD8 T cell ratio, and naïve/stem cell memory phenotype than patients with relapsed multiple myeloma.
- Anti-BCMA allogeneic CAR T cells derived from healthy donors showed efficient killing of primary multiple myeloma cells across different patient sub-groups, including high-risk disease.
- Also Read: FDA Lifts Clinical Hold On Allogene's CAR-T Trials.
- In a subset of patient samples with low BCMA, the addition of a gamma-secretase inhibitor increased the surface levels of BCMA and led to improved cytotoxic activity.
- The Company has two AlloCAR T trials underway investigating product candidates for multiple myeloma.
- The first is a Phase 1 UNIVERSAL trial that includes cohorts evaluating ALLO-715 as a monotherapy and in combination with SpringWorks Therapeutics Inc's (NASDAQ:SWTX) nirogacestat.
- The second is Phase 1 IGNITE dose-escalation trial evaluating ALLO-605, Allogene's first TurboCAR candidate.
- Allogene intends to provide a BCMA program clinical update by the end of 2022.
- Price Action: ALLO shares are down 2.21% at $9.74 during the market session on the last check Wednesday.
